 | Up a level |
Pittet, V; Juillerat, P; Michetti, P; Vader, J-P; Burnand, B; Rogler, G; Beglinger, C; Seibold, F; Mottet, C; Felley, C; Gonvers, J-J; Froehlich, F; Swiss IBD Cohort Study Group, The (2010). Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort. Alimentary pharmacology & therapeutics, 32(8), pp. 1007-16. Oxford: Wiley-Blackwell 10.1111/j.1365-2036.2010.04434.x
Pittet, V; Juillerat, P; Mottet, C; Felley, C; Ballabeni, P; Burnand, B; Michetti, P; Vader, JP; and, the Swiss IBD Cohort Study Group (2009). Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). International journal of epidemiology, 38(4), pp. 922-31. Oxford: Oxford University Press 10.1093/ije/dyn180
Beglinger, C; Binek, J; Braegger, C; Michetti, P; Rogler, G; Sauter, B; Seibold, F; Straumann, A (2008). Infliximab Monotherapie versus Kombinationstherapie mit Immunmodulatoren. Medical journal TMJ - Schweizer Zeitschrift für Innere Medizin(1), pp. 32-33. Neuhausen (CH): Rosenfluh
Bauerfeind, P; Beglinger, C; Beltinger, J; Braegger, C; Eigenmann, F; Fried, M; Guyot, J; Hürlimann, R; Michetti, P; Seibold, F; Straumann, A (2006). Infliximab - Recommendations practiques pour le traitment de la maladie de Crohn. Revue médicale suisse, 2(74), pp. 1807-15. Genève: Médecine & Hygiène
